Request Additional Trial Information
Full Trial Details: ClinicalTrials.gov
Condition: Breast Cancer
Study Type: Interventional
Phase: Phase III
Study Start Date: 07/29/2015
Study Completion Date: 09/30/2025
This is a prospective, two arm, international, multicenter, randomized, open-label Phase III study evaluating the addition of 2 years of palbocicilib to standard adjuvant endocrine therapy for patients with HR+/HER2 early breast cancer (EBC). The purpose of the PALLAS study is to determine weather the addition of palbociclib to adjuvant endocrine therapy will improve outcomes over endocrine therapy alone for HR+HER2 early breast cancer. Assessment of a variety of correlative analysis, including evaluation of the effect of the palbociclib on genomically defined tumor subgroups, is planned.